Overview

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genoty

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together with GSK233680k without ribavirin in a limited number of patients with chronic hepatitis C virus (HCV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Cytochrome P-450 CYP3A Inhibitors
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin
Ritonavir
Simeprevir